Conditions: HIV Salivary Gland Disease Benign Lymphoepithelial Lesion
Keywords: HIV Salivary Gland Disease Benign Lymphoepithelial Lesion BK Polyomavirus
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 17
Healthy volunteers: no

Brief summary:
The purpose of this study is to analyze BK viral infection in salivary gland diseases; specifically, to determine a definitive relationship between BK Virus and HIV associated salivary gland disease (HIVSGD). Participants are adults HIV+SGD+ who will be randomized 1:1 to receive BK Virus antiviral (ciprofloxacin) or placebo for 28 days. Salivary function/protein secretion will be correlated with BK polyomavirus titers. It is expected that patients with HIV+SGD+ will have elevated oral BK polyomavirus viral loads and will benefit from Ciprofloxacin.

Detailed description:
The study duration is 12 weeks with a baseline visit, a visit at 4 weeks and a visit at 12 weeks. At baseline participants are randomized to Ciprofloxacin or placebo and take the drug or placebo for 28 days. At subsequent visits BK polyomavirus presence and salivary gland function will be assessed.

Arms:
arm 1: Active treatment twice daily for 28 days arm 2: Placebo treatment twice daily for 28 days

Interventions: intervention 1: Ciprofloxacin intervention 2: Placebo
Intervention descriptions: intervention 1: Over encapsulated Ciprofloxacin 500 mg will be taken twice daily for 28 days. intervention 2: Placebo will over encapsulated to match active treatment, taken twice daily for 28 days.

Protocol document: